Dynamic Technology Lab Private Ltd Sells 45,342 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Dynamic Technology Lab Private Ltd reduced its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 68.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 20,850 shares of the company’s stock after selling 45,342 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Privia Health Group were worth $408,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PRVA. Benjamin Edwards Inc. lifted its stake in Privia Health Group by 360.7% in the third quarter. Benjamin Edwards Inc. now owns 14,366 shares of the company’s stock worth $262,000 after purchasing an additional 11,248 shares during the last quarter. XTX Topco Ltd bought a new stake in Privia Health Group in the third quarter worth $182,000. Barclays PLC lifted its stake in Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after purchasing an additional 158,188 shares during the last quarter. Geode Capital Management LLC lifted its stake in Privia Health Group by 1.0% in the third quarter. Geode Capital Management LLC now owns 2,415,022 shares of the company’s stock worth $43,986,000 after purchasing an additional 23,178 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new position in shares of Privia Health Group in the third quarter valued at about $66,000. 94.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PRVA has been the topic of a number of analyst reports. Macquarie started coverage on shares of Privia Health Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $25.00 price objective on the stock. Piper Sandler boosted their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Canaccord Genuity Group upped their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective on shares of Privia Health Group in a report on Friday, March 21st. Finally, Stephens restated an “overweight” rating and issued a $26.00 price objective on shares of Privia Health Group in a report on Thursday, January 2nd. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $26.67.

Insider Activity at Privia Health Group

In related news, CFO David Mountcastle sold 5,630 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total transaction of $125,999.40. Following the transaction, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.20% of the stock is owned by insiders.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $23.05 on Thursday. The firm’s 50 day moving average price is $23.73 and its 200-day moving average price is $21.41. The company has a market cap of $2.78 billion, a PE ratio of 230.52, a P/E/G ratio of 3.47 and a beta of 0.88. Privia Health Group, Inc. has a 52-week low of $15.92 and a 52-week high of $26.04.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.